Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results , sending shares higher on Wednesday, they punished Novo a day earlier — underscoring a growing divide in Wall Street's confidence in the two obesity drug leaders. In the U.S., Lilly held a 60.9% share of the obesity and diabetes drug market in the second quarter, compared with Novo's 38.8%, according to Lilly's earnings presentation Wednesday. Revenue of Novo's closely watched Wegovy pill came in slightly below analyst expectations. The drug has also shown higher efficacy than a rival obesity pill from Lilly, which launched a few months later than Novo's treatment.